The Conference Forum Announces the Launch of the 2nd Annual Medicaid Rebate Summit
News Oct 30, 2013
In anticipation of the Final Rule and Medicaid expansion, the Conference Forum announced the launch of the 2nd annual Medicaid Rebate Summit for January 22-23 in Washington DC. The MRS Summit helps pharmaceutical, biotech and generic drug manufacturers along with states and pharmacy leaders to navigate the complexities of the Medicaid Rebate process.
Co-Chair, Jim Abrams, Director, Government Pricing & Reporting, Mylan Pharmaceuticals, noted "The Summit's agenda is timely and includes topics that will benefit all Government Pricing staffers and Pharma professionals who are impacted by developments in government pricing programs."
Program Co-Chair, Stephanie Kupski, Sr. Director Managed Markets & HCP Compliance, Iroko Pharmaceuticals LLC, added, "With the GP community eagerly awaiting the release of the final AMP rule in January, the Medicaid Rebate Summit couldn’t be more relevant. I look forward to discussing implementation strategies with my colleagues.”
“The need to bring together CMS, manufacturers, states, pharmacy leaders and other key stakeholders to work through the many changes affecting the MDRP is so crucial that we moved the event up a month to January,” explains Valerie Bowling, Executive Director of the Conference Forum.
The 2014 Keynote is Adam J. Fein, PhD, President, Pembroke Consulting and Author, Drug Channels. Dr Fein was chosen as the 2014 Keynote for being the most recommended speaker by manufacturers for his insights into pharmaceutical economics and the impact on Medicaid Drug Rebates. 2013 Keynote, Alice Valder Curran of Hogan Lovells is back to help demystify the interpretation of the Final Rule.
Batavia Biosciences Teams Up with International Consortium to Support Polio EradicationNews
Batavia Biosciences announces its partnership with an international consortium coordinated by PATH aiming to develop and manufacture safer novel oral poliovirus vaccines (nOPV).READ MORE
Researchers Develop Novel ‘One-pot’ Approach to Conjugated Tetraenes SynthesisNews
TUAT researchers have achieved the new synthetic route of conjugated tetraenes from inexpensive and easily available 1,3-butadiene and substituted acetylenes by a one-pot approach under mild conditions. Conjugated tetraenes are important key substructures in biologically active natural products such as vitamins, and anti-mycotic drugs.READ MORE
Safety and Efficacy of MERS Treatment Confirmed in Phase I TrialNews
An experimental treatment developed from cattle plasma for Middle East respiratory syndrome (MERS) coronavirus infection shows broad potential, according to a small clinical trial. The treatment, SAB-301, was safe and well tolerated by healthy volunteers, with only minor reactions documented.READ MORE